BICD1 (BICD Cargo Adaptor 1)

These findings indicate that eRNAs may contribute to prostate cancer biology and could serve as useful markers for prognosis and pathway characterization.

RBP signature genes can serve as biomarkers for testicular cancer and play a role in predicting tumor metastasis and therapeutic efficacy.

Knockdown of KDM4E strengthened the PAR1-dependent activity of TNBC cells in response to thrombin activation, whereas TNBC progression activated by PAR1 signaling was blocked by combined overexpression of BICD1. Taken together, our data indicate that baicalein-promoted KDM4E enhanced the expression of BICD1 and activated the inhibitory effect of BICD1 on PAR1 signaling, thereby inhibiting TNBC progression.

In comparison between pts with non-HPD and pts with HPD, 306 genes in immune-related GO-Terms were enriched in pts with non-HPD and the median expression value of this genes set was significantly higher in pts with non-HPD; 16 SNPs in 12 genes (COX10-AS1, PASK, DOCK10, CDS2, PASK, CSGALNACT1, ARHGAP26, HLA-DQA1, DIAPH2, NFATC1, ARHGAP6, LCP2, RASA3) were correlated to non-HPD. Conclusions Our translational study demonstrated for the first time that gene expression of whole blood and SNPs as host-related markers can potentially predict response to Nivo in AGC.

Intriguingly, we found a significant correlation between BICD1 downregulation and a decreased level of CD274, GSK3B, HGF, or STAT3 in LGGs. Our findings suggest that BICD1 downregulation could be a potential biomarker for a favorable prognosis of LGGs.